Mikael Dolsten - PFIZER DRN President - Worldwide Research and Development

PFIZ34
  

BRL 64.79  2.20  3.28%   

  President
Dr. Mikael Dolsten, M.D., Ph.D., is the President Worldwide Research and Development of the Company. He was President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President President of Pfizer BioTherapeutics Research Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008. Director of Karyopharm Therapeutics Inc. Chairman of the Translational Advisory Board of Apple Tree Partners from 2016 to 2017.
Age: 59  President Since 2010  Ph.D    
212 733 2323  https://www.pfizer.com

Mikael Dolsten Latest Insider Activity

Tracking and analyzing the buying and selling activities of Mikael Dolsten against PFIZER DRN stock is an integral part of due diligence when investing in PFIZER DRN. Mikael Dolsten insider activity provides valuable insight into whether PFIZER DRN is net buyers or sellers over its current business cycle. Note, PFIZER DRN insiders must abide by specific rules, including filing SEC forms every time they buy or sell PFIZER DRN'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

PFIZER DRN Management Efficiency

PFIZER DRN has return on total asset (ROA) of 10.0 % which means that it generated profit of $10.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 31.87 %, meaning that it generated $31.87 on every $100 dollars invested by stockholders. PFIZER DRN management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 36.44 B in total debt with debt to equity ratio (D/E) of 0.44, which is about average as compared to similar companies. PFIZER DRN has a current ratio of 1.37, which is within standard range for the sector. Debt can assist PFIZER DRN until it has trouble settling it off, either with new capital or with free cash flow. So, PFIZER DRN's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PFIZER DRN sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PFIZER to invest in growth at high rates of return. When we think about PFIZER DRN's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

PRESIDENT Since

Sergio BorejoABC BRASIL PN
2018
Jose LaloniABC BRASIL PN
2018
Gustavo LanhosoABC BRASIL PN
2007
Renato PasqualinABC BRASIL PN
N/A
Sergio JacobABC BRASIL PN
2018
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 79000 people. PFIZER DRN (PFIZ34) is traded on Sao Paolo Stock Exchange in Brazil and employs 79,000 people.

PFIZER DRN Leadership Team

Elected by the shareholders, the PFIZER DRN's board of directors comprises two types of representatives: PFIZER DRN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PFIZER. The board's role is to monitor PFIZER DRN's management team and ensure that shareholders' interests are well served. PFIZER DRN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PFIZER DRN's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President of Global Established Pharma Bus.
Frank DAmelio, CFO and Executive VP of Bus. Operations
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President CTO and Digital Officer
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Dan Littman, Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

PFIZER Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PFIZER DRN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in PFIZER DRN without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the PFIZER DRN information on this page should be used as a complementary analysis to other PFIZER DRN's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for PFIZER Stock analysis

When running PFIZER DRN price analysis, check to measure PFIZER DRN's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PFIZER DRN is operating at the current time. Most of PFIZER DRN's value examination focuses on studying past and present price action to predict the probability of PFIZER DRN's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move PFIZER DRN's price. Additionally, you may evaluate how the addition of PFIZER DRN to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Please note, there is a significant difference between PFIZER DRN's value and its price as these two are different measures arrived at by different means. Investors typically determine PFIZER DRN value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PFIZER DRN's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.